Anika Therapeutics Stock Earnings Reports

Anika reported Q1 2026 revenue of $29.6M, up 13% year-over-year, driven by double-digit growth in the commercial channel (+12%) and a 14% increase in the OEM channel (timing-driven). Key commercial highlights: Integrity (rotator cuff augmentation) continues strong U.S. adoption with procedures up 35% YoY and more than 3,000 cases to date; Hyalofast remains a steady international contributor; and international OA pain management (CINGAL, MONOVISC, ORTHOVISC) delivered ~ $8.9M and continued market share gains. Operationally, GAAP gross margin expanded to 64% (from 56% a year ago) due to higher manufacturing productivity, throughput and lean initiatives; adjusted EBITDA improved to $4.3M. Operating expenses included $4.9M of one-time severance charges; R&D increased to support Hyalofast, CINGAL and early-stage HA-based suture/tape programs. Liquidity: $41M cash, no debt. Capital allocation: completed $15M 10b5-1 repurchase (avg price $10.76); company emphasizes continued CapEx for manufacturing and investments in the U.S. regenerative commercial channel. Guidance: reaffirmed full-year 2026 revenue $114M–$122.5M (1%–9% growth), commercial channel $53M–$58M (10%–20% growth), OEM $61M–$64.5M (flat to -5%); adjusted EBITDA expected 5%–10% of revenue. Regulatory/development: Hyalofast PMA review ongoing (FDA deficiency response in progress); CINGAL bioequivalence study enrollment on track and CINGAL achieved EU MDR certification with expanded joint indications. Management emphasized continued focus on surgeon training and adoption for Integrity, disciplined R&D investment, and embedding lean manufacturing/continuous improvement to sustain margins.